The efficacy and safety of IL-17 and IL-23 inhibitors in psoriatic arthritis across multiple disease domains
Dermatology Online Journal · 09.05.2026 · 32 (2)
DOI: 10.25251/zsav4a48 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology Online Journal, online erschienen am 09.05.2026. Verfasst von Danny Zakria und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Psoriatic, Interleukin-17, Interleukin-23. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
disease affecting peripheral joints, entheses, skin, and nails. Despite multiple available biologic therapies, unmet needs persist, particularly in patients with multisystem involvement or prior biologic failure. Interleukin-17 (IL-17) and interleukin-23 (IL-23) pathway inhibitors are widely used in PsA; however, important differences exist in their clinical efficacy across disease domains.
Methods
A comprehensive literature review was conducted using PubMed, Scopus, and Google Scholar to identify randomized controlled trials, long-term extension studies, mechanistic studies, and meta-analyses evaluating IL-17 and IL-23 inhibitors in PsA and related spondyloarthritides. A multidisciplinary panel of expert dermatologists and rheumatologists convened for a structured roundtable discussion. A modified Delphi process was used to develop and approve consensus statements. Strength of Recommendation Taxonomy (SORT) criteria were applied to each statement.
Results
Eight consensus statements were unanimously adopted. These statements address radiographic progression, axial disease, mechanistic considerations of IL-17A and IL-17F inhibition, comparative efficacy of bimekizumab, treatment sequencing, and safety considerations including candidiasis, hepatic effects, and psychiatric outcomes.
Conclusion
Based on the totality of available evidence, IL-17 inhibitors play an important role in the management of PsA across multiple disease domains. Differences between IL-17 and IL-23 pathway inhibition have important implications for treatment selection, particularly in patients with axial disease, significant skin involvement, or prior biologic failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Department of Dermatology, Medical University of South Carolina, Charleston, SC, USA.
- Department of Dermatology, University of Texas Southwestern, Dallas, TX, USA.
- Department of Dermatology, University of Illinois-Chicago, Chicago, IL, USA.
- Midwest Center for Dermatology and Cosmetic Surgery, Warren, MI, USA.
- Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Zitieren
APA
Zakria, D., Shah, M., Rosenberg, A., Burshtein, J., DeBusk, L., Altman, D. A., Armstrong, A. W., Gottlieb, A. B., Han, G., Khattri, S., Shaigany, S., Weinberg, J. M., & Lebwohl, M. (2026). The efficacy and safety of IL-17 and IL-23 inhibitors in psoriatic arthritis across multiple disease domains. Dermatology Online Journal, 32(2). https://doi.org/10.25251/zsav4a48
Vancouver
Zakria D, Shah M, Rosenberg A, Burshtein J, DeBusk L, Altman DA, et al. The efficacy and safety of IL-17 and IL-23 inhibitors in psoriatic arthritis across multiple disease domains. Dermatology Online Journal. 2026;32(2). doi:10.25251/zsav4a48
BibTeX
@article{Zakria2026,
author = {Zakria, Danny and Shah, Milaan and Rosenberg, Angela and Burshtein, Joshua and DeBusk, Lauren and Altman, David A and Armstrong, April W and Gottlieb, Alice B and Han, George and Khattri, Saakshi and Shaigany, Sheila and Weinberg, Jeffrey M and Lebwohl, Mark},
title = {The efficacy and safety of IL-17 and IL-23 inhibitors in psoriatic arthritis across multiple disease domains},
journal = {Dermatology Online Journal},
year = {2026},
volume = {32},
number = {2},
doi = {10.25251/zsav4a48}
}
EUVIMED